Introduction
Inflammatory myofibroblastic tumor (IMFT) is a rare solid tumor. The prevalence rate is 0.04% to 0.70%, with a higher incidence in children and young people (1). IMFT was considered a reparative benign post-inflammatory condition. However, recent studies have indicated that IMFTs are lesions with intermediary malignant potential due to their tendency to invade tissues, recur locally, and metastasize to distant sites (2).
IMFT can present at any age with a preference for children and adolescents (3). The tumor frequently presents in the abdominopelvic region, lungs, and retroperitoneum. However, it can involve any site of the body (4). The clinical presentation depends on the site of involvement, a palpable abdominal mass being the most frequent physical finding, and fever being the most common symptom. Given the indolent course, the tumor is often diagnosed in an advanced stage (3).
We present data on children diagnosed with IMFT, the varied presentations, challenges during management and follow-up; and the efficacy of an oral out-patient based combination chemotherapy.